| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CDG1T; Glucose phosphomutase 1; GSD14; PGM1; Phosphoglucomutase 1;;PGM 1 |
| WB Predicted band size | 61 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PGM 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于PGM1抗体的3篇代表性文献的简要概述(文献为示例，非真实存在)：
1. **"Anti-PGM1 autoantibodies in autoimmune hepatitis: Clinical relevance and epitope mapping"**
*作者：Chen L, et al. (2022)*
摘要：研究发现抗PGM1自身抗体在部分自身免疫性肝炎患者血清中特异性存在，可能作为疾病亚型的生物标志物，并通过表位定位揭示了其与PGM1酶活性区域的关联。
2. **"Monoclonal antibody targeting PGM1 inhibits tumor glycolysis in colorectal cancer models"**
*作者：Wang X, et al. (2020)*
摘要：开发了一种针对PGM1的单克隆抗体，证实其能抑制PGM1酶活性和肿瘤细胞糖酵解，在结直肠癌小鼠模型中显著减缓肿瘤生长。
3. **"PGM1 deficiency-associated myopathy and the role of antibody-based diagnostic approaches"**
*作者：Garcia R, et al. (2019)*
摘要：探讨PGM1基因缺陷导致的代谢性肌病，提出使用特异性抗体检测组织PGM1蛋白表达水平，辅助临床诊断和疾病严重度评估。
---
注：以上为模拟文献，实际研究中建议通过PubMed或Google Scholar以关键词“PGM1 antibody”或“anti-PGM1 autoantibody”检索最新论文。若需真实文献，可提供具体研究方向的补充说明。
PGM1 (phosphoglucomutase 1) is a key enzyme in glucose metabolism, catalyzing the interconversion of glucose-1-phosphate and glucose-6-phosphate, a critical step in glycolysis, glycogen synthesis, and galactose metabolism. Antibodies targeting PGM1 are widely used as research tools to study its expression, localization, and function in cellular processes. Dysregulation of PGM1 has been linked to metabolic disorders, including PGM1 deficiency, a rare autosomal recessive condition causing glycogen storage disease-like symptoms, congenital myopathy, and cardiac defects.
PGM1 antibodies are essential in diagnosing PGM1-related disorders through immunohistochemistry (IHC) or Western blotting, helping identify reduced enzyme activity or abnormal protein expression. In cancer research, these antibodies aid in exploring PGM1's role in tumor metabolism, as many cancers exhibit altered glycolytic pathways (the Warburg effect). Studies also investigate PGM1's interaction with other metabolic proteins or signaling pathways.
Most PGM1 antibodies are raised against specific epitopes of human PGM1. with monoclonal and polyclonal variants available. Validation includes testing on knockout cell lines or tissue samples with confirmed PGM1 levels. Commercial PGM1 antibodies often cite applications in ELISA, immunofluorescence, and flow cytometry. Researchers must consider cross-reactivity with homologous enzymes (e.g., PGM2 or PGM3) when interpreting results. Ongoing work aims to refine antibody specificity and develop clinical-grade assays for precision medicine applications.
×
